SIEMENS MEDICAL SOLUTIONS USA, INC

Lobbying for SIEMENS MEDICAL SOLUTIONS USA, INC

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$700,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

Commerce, Dept of (DOC)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 17

HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
HR 6197
Health Tech Investment Act
S 1399
Health Tech Investment Act
HR 5269
RESULTS Act
S 2761
RESULTS Act
HR 1406
Lung Cancer Screening and Prevention Act of 2025
HR 2319
Women and Lung Cancer Research and Preventive Services Act of 2025
S 1157
Women and Lung Cancer Research and Preventive Services Act of 2025
HR 6178
Increasing Access to Lung Cancer Screening Act
HR 842
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
S 339
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
HR 4417
Mobile Cancer Screening Act
S 2927
Mobile Cancer Screening Act
HR 2477
Portable Ultrasound Reimbursement Equity Act of 2025
S 1168
Portable Ultrasound Reimbursement Equity Act of 2025
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026

Lobbying activity 5

Health Issues

Issues related to FDA & third-party regulation of AI and Machine Learning-enabled devices; Issues related to Artificial Intelligence for medical devices; Issues related to data privacy standards and transparency; and Issues related to right to repair for medical devices.

Medicare/Medicaid

H.R. 5343 / S. 1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025 H.R. 6197 / S. 1399 - Health Tech Investment Act; H.R. 5269 / S. 2761 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 1406 - Lung Cancer Screening and Prevention Act of 2025; H.R. 2319 / S. 1157 - Woman and Lung Cancer Research and Preventive Services Act of 2025 H.R. 6178 - Increasing Access to Lung Cancer Research Screening Act H.R. 842 / S. 339 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. H.R. 4417 / S. 2927 - Mobile Cancer Screening Act; H.R. 5269 / S. 2761 - RESULTS Act; and H.R. 2477, S. 1168 - Portable Ultrasound Reimbursement Equity Act of 2025. Issues related to lung and breast cancer screening; and Issues related to Medicare reimbursement rates, including for mobile stroke units and in relation to artificial intelligence.

Trade (domestic/foreign)

Implementation of P. L. No 116-113 United States-Mexico-Canada Agreement Implementation Act - issues related to joint review; Issues related to medical supply chains and procurement; Issues related to critical minerals supply chains and production; and Issues related to international trade.

Tariff (miscellaneous tariff bills)

Implementation of P. L. 87-794 - Trade Expansion Act - issues related to domestic supply chain considerations for medical devices in regard to Section 232 investigations; and Implementation of P.L. 93-618 - Trade Act - issues related to domestic supply chain considerations for medical devices in regards to Section 301 investigations and reciprocal tariffs.

Budget/Appropriations

H.R. 5304 / S. S587 / H. Rept. 119-271 / S. Rept. 117-55 - Labor-HHS-Education Appropriation Act, FY 2026;

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.